About Haemonetics Corp
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.haemonetics.com
Frequently Asked Questions
What is the 52-week range for HAE?
The 52-week high is $110.45 and the 52-week low is $47.72.
What is the P/E ratio for HAE?
The Price to Earnings (P/E) ratio is 49.60.
What is the dividend yield for HAE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 11.35%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 7.12%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.21.
Analyst Recommendation Trends
Wall Street analyst consensus for HAE over the last few months:
Latest HAE News
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 5, 2026.
Haemonetics (NYSE:HAE): A Quality Investing Candidate Built on Durable Fundamentals
Haemonetics (HAE) passes Caviar Cruise quality screen with strong ROIC, cash flow, and EBIT growth, despite minor margin and debt concerns.
Haemonetics (HAE) Could Be 66% Undervalued After Margin Expansion Focus
Haemonetics (HAE) has been drawing investor attention after a strong total return over the past year, along with double-digit annual growth in both revenue and net income. Despite a small dip in the latest session, Haemonetics’ share price is US$108.52, with a strong 90 day share price return of 48.92% and a 1 year total shareholder return of 114.25%. This points to momentum building as investors reassess growth prospects and risk. Scan Haemonetics’ momentum against peers and uncover other...
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
PAHC vs. HAE: Which Stock Is the Better Value Option?
HAE, TWST Stocks Jump To Over 5-Year Highs – What’s Driving The Gains Today?
Haemonetics and Twist Bioscience stocks surged to more than five-year highs on Thursday, as fresh growth opportunities drew cheer from Wall Street.
Lyft downgraded, Trip.com upgraded: Wall Street's top analyst calls
Lyft downgraded, Trip.com upgraded: Wall Street's top analyst calls
Roblox downgraded, Hershey upgraded: Wall Street's top analyst calls
Roblox downgraded, Hershey upgraded: Wall Street's top analyst calls
This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.
Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123
Citigroup analyst Joanne Wuensch upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and raises the price target from $92 to $123.
1 Momentum Stock with Competitive Advantages and 2 We Avoid
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings,
Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $125
Raymond James analyst Andrew Cooper maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $105 to $125.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-24 | Johnson Lloyd Emerson | +2,538 | - | - |
| 2026-07-24 | Bryant Diane M | +2,538 | - | - |
| 2026-07-24 | Pomeroy Claire | +2,538 | - | - |
| 2026-07-24 | Zane Ellen M | +2,538 | - | - |
| 2026-07-24 | Madaus Martin D | +2,538 | - | - |
| 2026-07-24 | KROLL MARK W | +2,538 | - | - |
| 2026-07-24 | COYLE MICHAEL J | +2,538 | - | - |
| 2026-07-24 | ABERNATHY ROBERT E | +2,538 | - | - |
| 2026-06-05 | Maunsell Farris Maryanne | -259 | $71.28 | $18,462 |
| 2026-06-05 | Miller Laurie A. | -313 | $71.28 | $22,311 |
| 2026-05-15 | Chan Frank | +27,535 | - | - |
| 2026-05-15 | Chan Frank | -546 | $56.29 | $30,734 |
| 2026-05-15 | Maunsell Farris Maryanne | +2,220 | - | - |
| 2026-05-15 | Maunsell Farris Maryanne | -197 | $56.29 | $11,089 |
| 2026-05-15 | Galvin Roy | +27,535 | - | - |
| 2026-05-15 | Galvin Roy | -879 | $56.29 | $49,479 |
| 2026-05-15 | Miller Laurie A. | +13,323 | - | - |
| 2026-05-15 | Miller Laurie A. | -948 | $56.29 | $53,363 |
| 2026-05-15 | Basil Michelle L | +28,424 | - | - |
| 2026-05-15 | Basil Michelle L | -2,913 | $56.29 | $163,973 |
| 2026-05-15 | Simon, Christopher | +78,344 | - | - |
| 2026-05-15 | Simon, Christopher | -9,681 | $56.29 | $544,943 |
| 2026-05-15 | DArecca James | +29,312 | - | - |
| 2026-05-15 | DArecca James | -2,505 | $56.29 | $141,006 |
| 2026-05-01 | DArecca James | -655 | $59.26 | $38,815 |
| 2025-11-10 | KROLL MARK W | +1,400 | $70.56 | $98,784 |
| 2025-10-31 | Galvin Roy | -145 | $50.01 | $7,251 |